Is kidney injury from Bendamustine reversible?

Reversible. Typical onset: TLS within hours to days of the first cycle; TMA delayed and rare..

How should kidney function be monitored during Bendamustine therapy?

Uric acid, potassium, phosphate, calcium and creatinine before and during the first cycle (TLS panel); CBC with LDH; schistocytes if TMA suspected; Renal function across cycles in CLL with renal infiltration.

How can kidney injury from Bendamustine be prevented?

TLS prophylaxis: hydration plus allopurinol or rasburicase per risk

Who is at higher risk of kidney injury from Bendamustine?

High tumor burden / high white count (CLL, bulky lymphoma); Pre-existing renal impairment; Volume depletion and high baseline uric acid/LDH; First treatment cycle.

Back to explorer

Printable monograph

Alkylator

Bendamustine

Treanda · Benda

Alkylator · approved 2008 · 10 citations · FAERS AKI reporting ROR 2.88 (95% CI 2.63–3.15, 489 AKI reports)

Up to date· through 2026

Deeply sourced8/9 · 7 signals

Met: 10 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 25y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2026
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A hybrid alkylator whose biggest renal threat is the tumor it dissolves, not the kidney itself.

ModerateBifunctional alkylator

Chronic lymphocytic leukemiaIndolent / rituximab-refractory B-cell non-Hodgkin lymphomaMantle cell lymphoma (in combinations)

§01

Signature kidney injury

Signature lesion

Crystal / Obstructive Nephropathy

Direct nephrotoxicity is uncommon; the principal renal risk is acute kidney injury from tumor lysis syndrome in high-burden disease, classically during the first cycle. TLS with renal failure is documented from the first reported case onward; TMA is rare and case-level.Source: Hummel et al., Eur J Haematol 2005

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Tumor lysis within hours to days of the first cycle; TMA delayed and rare.

Distilled from: “TLS within hours to days of the first cycle; TMA delayed and rare.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Crystal / Obstructive Nephropathy#1 · Signatureno population incidence denominator
First-cycle bendamustine-rituximab can precipitate severe tumor lysis syndrome with urate nephropathy and AKI in high-burden disease (case report). PMID 42004873 (opens PubMed in a new tab)
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Thrombotic MicroangiopathyRarequalitative — no citable incidence
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified

SeverityModerate

ReversibilityReversible

Evidence10 citations

Nephron map

Glomerulus

Vasculature / Endothelium

Distal Tubule / Collecting Duct

Tubular LumenThe urine flow path

Crystal / Obstructive Nephropathy

Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.

§03

Kidney injury

Mechanism of kidney injury

Rapid cytoreduction in bulky/high-count CLL/lymphoma releases uric acid, potassium and phosphate, causing tumor lysis syndrome with uric acid and calcium-phosphate crystal precipitation, intratubular obstruction and AKI; in CLL even modest tumor burden can produce severe first-cycle TLS. Endothelial injury producing thrombotic microangiopathy has been reported rarely. Leukemic renal infiltration and paraneoplastic glomerular disease (e.g., minimal-change) are alternative CLL-related mechanisms encountered around bendamustine therapy.

Clinical presentation

Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and rising creatinine after the first cycle (TLS); in TMA, microangiopathic hemolytic anemia, thrombocytopenia and AKI. Rarely, nephrotic-range proteinuria from coexisting CLL-associated glomerulopathy.

Management

Treat established TLS with aggressive IV fluids, rasburicase, electrolyte correction and dialysis if needed; for suspected drug-associated TMA, discontinue and provide supportive care. TLS-related AKI is usually reversible with prompt treatment.Lesion-level management framework

Risk factors

High tumor burden / high white count (CLL, bulky lymphoma)
Pre-existing renal impairment
Volume depletion and high baseline uric acid/LDH
First treatment cycle

Prevention

TLS prophylaxis: hydration plus allopurinol or rasburicase per risk

Anticancer mechanism· how it treats cancer

Bifunctional alkylating agent fusing a nitrogen-mustard group with a purine-analog benzimidazole ring, producing durable DNA cross-links and double-strand breaks with relatively limited cross-resistance to other alkylators. Used for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma (often with rituximab).

§04

Clinical depth

Renal dose adjustment

Do not use if CrCl <30 mL/min - PK in severe impairment is unknown. At CrCl >=30 the label specifies no dosage adjustment and carries no reduced-dose band at any clearance, population PK having shown no clinically meaningful effect of mild-to-moderate impairment. (A CrCl <40 mL/min floor appears in older references: that was the US label until it moved to <30 in 2017, and it is superseded.) Active metabolites contribute little to overall effect, but exposure data in advanced CKD are sparse - individualize with pharmacy.

Dialyzability & ESKD dosing

Parent drug is rapidly hydrolyzed/metabolized with short half-life, so it is not meaningfully dialyzable; reported ESKD/HD cases dosed bendamustine successfully with careful timing rather than relying on dialytic removal.

Differential diagnosis

TLS-AKI (hyperuricemia, hyperphosphatemia, hyperkalemia after cytoreduction, crystal/obstructive picture) vs rare drug-associated TMA (microangiopathic hemolysis, thrombocytopenia, normal/low uric acid) vs CLL-intrinsic injury (leukemic infiltration, paraneoplastic minimal-change disease). The TLS biochemistry and its timing to the first cycle are the discriminators.

Monitoring

Uric acid, potassium, phosphate, calcium and creatinine before and during the first cycle (TLS panel)
CBC with LDH; schistocytes if TMA suspected
Renal function across cycles in CLL with renal infiltration

Key trials & series

Hummel Eur J Haematol 2005 - first reported bendamustine TLS with acute renal failure in CLL
Garuma Clin Case Rep 2026 - first-cycle bendamustine-rituximab TLS with AKI/multiorgan failure
Cheson Clin Adv Hematol Oncol 2009 - TLS risk/management framework in CLL including bendamustine

Clinical pearls

Do not assume CLL is low-risk for TLS - severe, even fatal, first-cycle TLS is reported with bendamustine-rituximab.
The kidney injury is usually the tumor's doing (TLS), not direct tubular toxicity - prophylaxis and hydration are the main levers.
Bendamustine has been delivered in ESRD/HD in case reports, so renal failure is not an absolute barrier when no alternative exists.

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the Alkylator class.

Hematologic

Cytopenias, thrombosis, TMA

Myelosuppression; secondary malignancy risk

Neurologic

Neuropathy, encephalopathy, ICANS, PRES

Ifosfamide encephalopathy (chloroacetaldehyde)

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

High-dose cyclophosphamide cardiotoxicity

§05

References

8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

8 references · 2001–2026 · 1 since 2024

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 2

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseC · LimitedBendamustine-Induced Nephrogenic Diabetes Insipidus in a Patient With AL Amyloidosis.Uwumugambi NA et al. · Am J Kidney Dis 2017 · PMID 27780577Documents bendamustine directly causing partial nephrogenic diabetes insipidus (collecting-duct tubular dysfunction with polyuria) in a patient treated for AL amyloidosis.CaseC · LimitedBendamustine induced tumor lysis syndrome with acute renal failure in chronic lymphocytic leukemia.Naithani R et al. · Indian J Cancer 2014 · PMID 25494150Case of bendamustine-precipitated tumor lysis syndrome producing acute renal failure in a CLL patient.

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

Do not use in patients with creatinine clearance <30 mL/min. ( 8.6 )

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 23,763 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 6 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Thrombotic Microangiopathycorroborated · ROR 2.86
Electrolyte Disturbancecorroborated · ROR 2.32 — on the terms that name the lesion (ROR 2.81)
Crystal / Obstructive Nephropathycorroborated · ROR 1.4

Acute Tubular Necrosis

ROR 3.8895% CI 2.87–5.23· 43 reports

Thrombotic Microangiopathy

ROR 2.8695% CI 2.17–3.78· 50 reports

Electrolyte Disturbance

ROR 2.3295% CI 2.12–2.53· 495 reports

Acute Interstitial Nephritis

ROR 2.2795% CI 1.71–3.01· 48 reports

Hemorrhagic Cystitis

ROR 1.5295% CI 1.27–1.82· 119 reports

Crystal / Obstructive Nephropathy

ROR 1.4095% CI 1.13–1.72· 88 reports

FAERS outcomes & reporting trend· 20.7% of reports w/ death · 38.2% w/ hospitalization

20.7%

Reported with a death outcome

4,908 of 23,763 reports

38.2%

Reported with hospitalization

9,072 of 23,763 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 7 systems · 23,763 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 2.8895% CI 2.63–3.15· 489 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

Renal & urinary

Acute Kidney Injury489

Blood & lymphatic

Neutropenia1,517Thrombocytopenia1,218Febrile Neutropenia1,173Anaemia1,091Pancytopenia687

Immune / infection

Pneumonia1,185Covid-191,149Infection749Sepsis649Cytomegalovirus Infection524

General / constitutional

Pyrexia1,624Fatigue611

Gastrointestinal

Diarrhoea749Nausea652

Skin

Rash668

Respiratory

Dyspnoea502

Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

ADQIConventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) WorkgroupKidney Int 2026 · PMID 41881107Cisplatin is identified as a leading cytotoxic nephrotoxin; the workgroup details preventive measures (adequate isotonic hydration, correction of volume depletion, avoidance of concurrent nephrotoxins, attention to electrolyte/magnesium wasting) and management of cisplatin-associated AKI, with a research agenda for knowledge gaps.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Bendamustine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Decitabine

Dacogen · Hypomethylating agent

Profile

Tumor lysis in MDS/AML.

XTALPRELYTE

Mild#1 · 72% phenotype match

Mechlorethamine

Mustargen · Alkylating agent (nitrogen mustard)

Profile

Tumor lysis in bulky lymphoma is the main renal hazard; modern topical gel has no detectable systemic absorption.

LYTEXTAL

Moderate#2 · 65% phenotype match

Fludarabine

Fludara · Purine analog

Profile

Tumor lysis; accumulates in renal impairment.

XTALPRELYTE

Moderate#3 · 65% phenotype match

Dactinomycin (actinomycin D)

Cosmegen · Antitumor antibiotic

Profile

Renal risk indirect via tumor lysis in chemosensitive pediatric tumors; hepatic veno-occlusive disease is the signature organ toxicity.

LYTEPREXTAL

Moderate#4 · 63% phenotype match

Cytarabine

Cytosar · Nucleoside analog

Profile

Tumor lysis in leukemia; high-dose toxicity.

XTALPRELYTE

Moderate#5 · 60% phenotype match

Etoposide

Etopophos · Topoisomerase II inhibitor

Profile

Tumor lysis; renally cleared.

XTALPRELYTE

Mild#6 · 60% phenotype match

Compare Bendamustine with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Alkylating agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Bendamustine’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Bendamustine; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 51 clinical records among all 60 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.